Gabriele Magaro'
About Gabriele Magaro'
Gabriele Magaro is a Principal Application Scientist at Dotmatics in London, UK, with a background in organic and medicinal chemistry. He has extensive experience in research and development, having previously worked at Barilla Group and Angelini.
Work at Dotmatics
Gabriele Magaro' has been employed at Dotmatics since 2021, currently holding the position of Principal Application Scientist. His role involves providing scientific expertise and support for the company's software solutions in the life sciences sector. Prior to this position, he served as an Application Scientist from 2018 to 2020, and as a Senior Application Scientist from 2020 to 2021. His tenure at Dotmatics has spanned a total of five years, during which he has contributed to various projects aimed at enhancing research and development processes.
Education and Expertise
Gabriele Magaro' earned a Master's degree in Organic Chemistry from Sapienza Università di Roma. His educational background provides a strong foundation for his work in the field of chemistry, particularly in medicinal and combinatorial chemistry. This academic training supports his roles in research and application science, allowing him to apply theoretical knowledge to practical challenges in the life sciences.
Background
Gabriele Magaro' began his career in the food industry as an R&D Trainee at Barilla Group in 2005, where he worked for six months in Parma. He then transitioned to Angelini, where he held various positions from 2006 to 2018, including roles in medicinal and combinatorial chemistry. His extensive experience in research and development within the pharmaceutical sector has shaped his career trajectory and expertise in application science.
Previous Experience at Angelini
At Angelini, Gabriele Magaro' worked for a total of eleven years, starting with a Medicinal Chemistry Internship from 2006 to 2007. He then progressed to roles as a Researcher in Combinatorial Chemistry from 2007 to 2008 and in Medicinal Chemistry from 2008 to 2018. His work at Angelini involved significant contributions to research projects, focusing on the development of new medicinal compounds.